Table 1.

Synergistic interactions and statistical significance between combination treatments with and without BMS-906024 on SSGD.

	Chemo vs. Chemo + BMS-906024		Chemo vs. ChemoRT + BMS-906024
	SSGD	Synergism	SSGD	Synergism
H1299
Cisplatinɤ	***	ns	*	**
Etoposide	***	ns	**	ns (0.07)
Paclitaxel	ns	ns	***	***
Docetaxel	***(BMS effect)	*	***	*
Pemetrexedɤ	ns	ns	ns	ns
Crizotinib	**	ns	*	***
H460
Paclitaxel	ns	ns	***	***
Crizotinib	***	***	***	***

Chemotherapeutics (1.2 μM Cisplatin, 0.1 μM Etoposide, 2.5 nM Paclitaxel, 1 nM Docetaxel, 0.25 μM Pemetrexed, 0.4 μM (H1299) or 0.8 μM (H460) Crizotinib) were combined with 1 or 0.1 μM (^ɤ) of γ-secretase inhibitor BMS-906024 and/or single dose 2 Gy radiation, and compared to their respective treatment control without BMS-906024. A minimum of 12 individual spheroids were tested per condition. Ns, not significant;

^***p-value < 0.001,

^**p-value < 0.01 and

^*< 0.050. “BMS effect” note indicates that there was no difference between BMS-906024 treatment and the combination treatment of BMS-906024 with chemotherapeutic.